Overview

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Status:
Completed

Trial end date:
2018-01-04

Target enrollment:

Participant gender:

Summary

The purpose of this study was to explore the safety and tolerability of enzalutamide in combination with abiraterone acetate plus prednisone. Subjects diagnosed with cancer of the prostate that was getting worse and spreading to the bone despite receiving hormone treatment were enrolled and received study treatment until disease progression.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Collaborators:

Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Medivation, Inc.

Treatments:

Abiraterone Acetate
Prednisone